Echoes of ancient wisdom and synergistic strategies invigorate the fight against liver fibrosis

Table 1 Epistemic evolution in antifibrotic drug discovery

Feature	Reductionist paradigm (current)	Systems pharmacology paradigm (proposed)	Mechanistic rationale
Therapeutic philosophy	Linear monotargeting: High-affinity blockade of isolated molecular targets	Network perturbation: Combinatorial modulation of topological hubs	Topological vulnerability: Fibrotic networks are scale-free; simultaneous multi-node perturbation collapses topology
System response	Hydra effect (compensatory rerouting): Dynamic activation of alternative signaling pathways to sustain fibrogenesis	Synergistic attenuation: Concurrent, low-grade dampening of parallel pathways prevents feedback loop activation	Biological robustness: Monotherapy triggers homeostatic compensation; combinatorial logic disrupts system
Safety profile	High-dose toxicity: Requires high receptor occupancy, risking physiological homeostasis disruption	Improved therapeutic index: Efficacy achieved via additive/synergistic interactions at sub-toxic concentrations	Pharmacodynamic synergy: Constituents exert entourage effects
Developmental focus	Affinity-based optimization: IC50 and molecular selectivity	Phenotype-driven efficacy: Maximizing phenotypic reversion	Functional bioequivalence: Shifts validation metrics from chemical purity to bioactivity linked network modulation

Table 2 Strategic roadmap for modernizing botanical therapeutics in liver fibrosis

Developmental phase	Current bottleneck/challenge	Strategic evolution	Key technologies
CMC & standardization	Static chemical markers. Quality control based on 1-2 abundant compounds. Fails to capture entourage effects or bioequivalence of substitutes	Bioactivity-linked markers. Correlate chemical fingerprints directly with phenotypic bioactivity. Standardize biological output, not just chemical input	High-resolution metabolomics. Phenotypic screening
Formulation strategy	Raw extracts vs pure compound. Extracts lack reproducibility. Pure compounds lose matrix synergy	Enriched fractions. Chemically defined active fractions. Retains synergistic matrix; removes inert/toxic loads	Fractionation chemistry. PK/PD modeling
Patient stratification	All-comers trial design. Treats fibrosis as a monolithic entity. Ignores heterogeneity of MASH	Precision endotyping. Identify subgroups driven by oxidative stress/inflammation. Match patient endotype to drug mechanism	Genomic profiling. Inflammatory biomarkers
Clinical endpoints	Invasive liver biopsy. Sampling error and variability. High barrier to patient recruitment	Non-invasive surrogate endpoints. Dynamic markers of fibrogenesis. Enables rapid, ethical efficacy assessment	MR/shear wave elastography. Liquid biopsy

CMC: Chemical, manufacturing, and controls; PK/PD: Pharmacokinetic/pharmacodynamic; MASH: Metabolic dysfunction-associated steatohepatitis; MR: Magnetic resonance.